We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.


Boehringer Ingelheim to Expand Drug Discovery Aggrement with Graffinity

Want a FREE PDF version of This News Story?

Complete the form below and we will email you a PDF version of "Boehringer Ingelheim to Expand Drug Discovery Aggrement with Graffinity"

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

Read time:

Graffinity Pharmaceuticals GmbH has announced that its partner Boehringer Ingelheim Pharmaceuticals, Inc. has chosen to exercise options in its original agreement with Graffinity that will increase the number of targets screened by Graffinity as part of this global alliance.

Under the terms of the agreement, Graffinity will receive additional technology access fees for the generation of multiple small molecule hit series against a variety of drug targets from different therapeutic areas.

Graffinity will apply its proprietary fragment based drug discovery technology and drug fragment chemical microarrays to identify small molecule hit structures focusing on compounds with modes of action.

Kristina Schmidt, Chief Executive Officer of Graffinity, remarked,”Boehringer Ingelheim is taking full advantage of our proprietary process for rapidly identifying quality fragment hits. We believe that this collaboration is a validation of Graffinity’s approach of accelerating drug discovery through innovations in fragment based drug discovery."

Both companies, Boehringer Ingelheim and Graffinity Pharmaceuticals, reiterated the importance of the continuation and expansion of this collaboration which complements Boehringer Ingelheim's in-house capabilities and will include a number of additional drug targets.